Business
Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call
MONTREAL, May 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight&#x...
About this update from Knight Therapeutics, Inc.
[{"type":"text","content":"Notice of Knight Therapeutics' First Quarter 2025 Results Conference Call\n\n\n\n MONTREAL, May 01, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its first quarter 2025 financial results on Thursday, May 8, 2025 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in this call.\n \n\n\n Date\n \n : Thursday, May 8, 2025\n \n\n\n\n Time\n \n : 8:30 a.m. ET\n \n\n\n\n Telephone\n \n : Toll Free: 1-888-699-1199 or International 1-416-945-7677\n \n\n\n\n Webcast\n \n\n :\n \n\n\n www.knighttx.com\n \n\n or\n \n\n Webcast\n \n\n\n This is a listen-only audio webcast. Media Player is required to listen to the broadcast.\n \n\n\n Replay\n \n : An archived replay will be available for 30 days at\n \n\n www.knighttx.com\n \n\n .\n \n ________________________________________\n \n\n\n\n About Knight Therapeutics Inc.\n \n\n\n Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at\n \n www.knighttx.com\n \n or\n \n www.sedarplus.ca\n \n .\n \n\n\n\n Forward-Looking Statement\n \n\n\n This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially fro...